Press releases

2010-09-07Update on the FDA review for Abstral™
2010-08-27Orexo announces that partner Kyowa Hakko Kirin is to conduct additional clinical trials on KW-2246 for treatment of cancer pain in Japan
2010-08-26Orexo notes significant change in its owner structure
2010-08-20Orexo AB (publ.) – Interim report, January-June 2010
2010-08-20Orexo launches next step in strategy, new development programs and announces change of CEO
2010-08-10Orexo appoints Robin Wright as new EVP Head of Finance and Strategy
2010-06-02Orexo confirms Abstral PDUFA date update
2010-06-01Orexo enters into an alliance and license agreement for new drugs to treat respiratory diseases
2010-05-18Orexo reports continued strong AbstralTM sales in Europe
2010-05-07Orexo to present at Rodman & Renshaw 6th Annual Global Healthcare Conference
2010-05-05Orexo AB (publ) – Interim report, January-March 2010
2010-04-21Report from Orexo AB’s Annual General Meeting, April 21, 2010
2010-04-07Novo transaction completed
2010-03-31Report from the extraordinary general meeting in Orexo AB (publ), 31 March 2010
2010-03-23Notice of Annual General Meeting in Orexo AB
2010-03-15Orexo Strengthens Financial and Strategic Position with Placement of Convertible Bonds and Existing Shares to the Growth Equity unit of Novo A/S
2010-03-15Notice of Extraordinary General Meeting
2010-02-25Orexo announces Kyowa Hakko Kirin’s submission of KW-2246 (Abstral) for approval in Japan
2010-02-17Orexo AB (publ.) – Year-end Report January-December 2009
2010-02-04Orexo confirms Canadian Regulatory Filing of Abstral
2010-02-02Orexo announces that partner Kyowa Hakko Kirin entered a Joint Distribution Agreement on KW-2246 for treatment of cancer pain in Japan
2010-01-07Orexo announces that partner ProStrakan has presented strong sales figures for Abstral in Europe